Pemfigoid Bulosa

01Pathophysiology

Bullous pemphigoid is the most common autoimmune blistering disease and predominantly affects the elderly population. The underlying mechanism involves autoantibody production (primarily IgG) directed against two hemidesmosomal proteins: BP180 (also called BPAG2 or type XVII collagen) and BP230 (BPAG1). These hemidesmosomes serve as the anchor connecting the basal keratinocytes of the epidermis to the underlying basement membrane zone. When antibodies bind to these targets, this anchor system is disrupted.

Once IgG autoantibodies bind to BP180 and BP230, they activate the classical complement pathway, generating C3a and C5a. These complement fragments serve as potent chemoattractants that recruit eosinophils, neutrophils, and mast cells to the basement membrane zone. These inflammatory cells release proteolytic enzymes (including matrix metalloproteinases and neutrophil elastase) that degrade the structural proteins of the dermal-epidermal junction. This enzymatic destruction causes a separation below the epidermis, meaning the full thickness of the epidermis remains intact as the roof of the blister.

This is the critical concept that directly explains the clinical presentation: because the split is subepidermal (below the epidermis), the blister roof is composed of the entire epidermis, making it thick and mechanically resistant. This is why the blisters are tense and do not rupture easily. Compare this to pemphigus vulgaris, where the split is intraepidermal (within the epidermis), producing a thin, fragile roof that ruptures readily and gives flaccid blisters.

The intense pruritus that precedes and accompanies the blisters is explained by mast cell degranulation and eosinophil activation at the basement membrane zone. Many patients experience a prolonged prodromal phase of urticarial plaques and intense itching for weeks to months before blisters actually appear, which makes early diagnosis challenging.

The association with neurological disease (dementia, Parkinson, stroke) is thought to reflect the fact that BP180 and BP230 are also expressed in neuronal tissue. Neurodegeneration may expose these antigens, triggering cross-reactive immune responses that then target the same proteins in skin. Drug-induced bullous pemphigoid, particularly from DPP-4 inhibitors (gliptins), is increasingly recognized and should be considered in any diabetic patient on these agents who develops blistering.

02Classification and Clinical Manifestation

03Diagnostic Workup

The diagnosis of bullous pemphigoid requires a tissue-based approach, not just clinical appearance alone.

Step 1: Skin biopsy for routine histology (H&E stain). This is the best initial diagnostic test. Ideally, biopsy an intact, early blister (include the edge of the blister and perilesional skin). Histology reveals a subepidermal cleft (separation beneath the epidermis) with an inflammatory infiltrate in the upper dermis that is rich in eosinophils. The presence of eosinophils in the blister cavity and dermis is a hallmark finding. This subepidermal location immediately separates bullous pemphigoid from pemphigus vulgaris, which shows an intraepidermal (suprabasal) split.

Step 2: Direct Immunofluorescence (DIF). This is the gold standard and most accurate test. A separate biopsy is taken from perilesional, uninvolved-appearing skin (not from the blister itself, because inflammation destroys the immunoreactants). DIF shows a continuous linear band of IgG and C3 deposited along the basement membrane zone. This linear pattern is the distinguishing feature. Remember: DIF requires a fresh biopsy placed in Michel transport medium or saline, not formalin.

Step 3: Salt-split skin technique. When DIF shows linear IgG at the basement membrane zone, you must determine which side of the split the antibodies are on. In this technique, normal human skin is incubated in 1M NaCl, which cleaves the skin through the lamina lucida (within the basement membrane zone). In bullous pemphigoid, the antibodies bind to the epidermal (roof) side, because BP180 and BP230 are located on the hemidesmosome, which stays with the epidermis. This distinguishes bullous pemphigoid from epidermolysis bullosa acquisita, where antibodies bind to the dermal (floor) side (because the target, type VII collagen, is in the anchoring fibrils below the split).

Step 4: Serological tests. ELISA for anti-BP180 (NC16A domain) and anti-BP230 antibodies can confirm the diagnosis and are useful for monitoring disease activity and response to treatment. Anti-BP180 titers in particular correlate with disease severity and can predict relapse.

Peripheral eosinophilia on CBC is a supportive finding, consistent with the eosinophil-driven pathology.

04Management and Treatment

Acute Management

The first-line treatment for bullous pemphigoid, regardless of severity, is high-potency topical corticosteroids. The landmark study by Joly et al. (2002) demonstrated that whole-body application of clobetasol propionate 0.05% cream (20-40 g/day) was superior to oral prednisone in controlling disease and had significantly fewer side effects and lower mortality. This is a frequently tested concept: the answer to "what is the best initial treatment for bullous pemphigoid?" is topical clobetasol, not oral prednisone. Apply the cream to the entire body surface (including uninvolved skin), not only on the blisters. The typical starting regimen is twice daily for 2-4 weeks, then gradually taper over 4-12 months.

For patients with moderate to severe disease who are not adequately controlled with topical therapy alone, or for whom whole-body topical application is impractical, systemic corticosteroids are added. The usual starting dose is prednisone 0.5 mg/kg/day (lower than the dose used in pemphigus vulgaris). Once disease control is achieved (no new blisters for 2-4 weeks), begin a slow taper.

Doxycycline 200 mg/day has emerged as a viable alternative first-line agent, particularly in frail elderly patients where even topical steroids carry a risk of systemic absorption and skin atrophy. The BLISTER trial demonstrated that doxycycline was non-inferior to oral prednisolone for short-term blister control, with a significantly better safety profile.

Steroid-Sparing Agents

Because bullous pemphigoid often requires months of treatment and the patient population is elderly with significant comorbidities, steroid-sparing agents are introduced early:

• Mycophenolate mofetil (1-3 g/day): commonly used, good evidence

• Azathioprine (1-3 mg/kg/day): check TPMT levels before starting to avoid myelosuppression

• Dapsone (50-150 mg/day): check G6PD levels before starting to avoid hemolytic anemia

• Methotrexate (5-15 mg/week): useful in elderly patients; monitor hepatic and renal function

Refractory Disease

For patients failing conventional therapy, rituximab (anti-CD20 monoclonal antibody) has shown strong efficacy. It can be dosed as 375 mg/m^2 weekly for 4 weeks or as two infusions of 1000 mg separated by 2 weeks. Other options include omalizumab (anti-IgE, particularly for the urticarial/pruritic component) and IVIG.

Wound Care

Large blisters should be drained with a sterile needle while keeping the blister roof intact (it serves as a biological dressing). Do not deroof blisters. Apply non-adherent dressings. Monitor for secondary infection.

Contraindications and Cautions

• Avoid prolonged high-dose systemic steroids in elderly patients due to osteoporosis, diabetes, and infection risk

• Dapsone is contraindicated in G6PD deficiency

• Azathioprine requires TPMT genotype/phenotype testing

• Methotrexate must be used cautiously in renal impairment

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common mistake students make with bullous pemphigoid is confusing it with pemphigus vulgaris. These two diseases are essentially a paired comparison on exams and you will almost certainly encounter a question designed to distinguish them. The key is blister quality: tense = subepidermal = bullous pemphigoid, and flaccid = intraepidermal = pemphigus vulgaris. If the vignette mentions an elderly patient with tense blisters and a negative Nikolsky sign, the answer is bullous pemphigoid. If the vignette describes painful oral erosions followed by flaccid blisters with a positive Nikolsky sign, the answer is pemphigus vulgaris.

Another common trap involves the pre-bullous phase. A vignette may describe an elderly patient with weeks of severe, treatment-resistant pruritus and urticarial plaques without visible blisters. Students often select eczema, urticaria, or a drug reaction. The clue is the severity of pruritus in an elderly patient that fails to respond to standard treatments. If the question offers DIF or skin biopsy as an answer choice, that is the next best step.

A frequently tested treatment pearl: the best initial treatment for bullous pemphigoid is topical clobetasol, not oral prednisone. Students reflexively choose systemic steroids for autoimmune blistering diseases, but the evidence shows that topical superpotent steroids are both more effective and safer in bullous pemphigoid.

On salt-split skin, remember this rule: bullous pemphigoid stains the roof (epidermal side) because the target antigens (BP180, BP230) sit on the hemidesmosome above the split. Epidermolysis bullosa acquisita stains the floor (dermal side) because type VII collagen sits in the anchoring fibrils below the split. If the question asks you to differentiate two diseases that both show linear IgG at the BMZ, salt-split skin is the answer.

Finally, always check the medication list in the stem. DPP-4 inhibitors (any drug name ending in "-gliptin") are an increasingly tested cause of drug-induced bullous pemphigoid, and the next best step is to discontinue the offending agent.

The core competency being tested is your ability to (1) recognize the classic presentation of tense blisters in an elderly patient, (2) distinguish bullous pemphigoid from pemphigus vulgaris and other subepidermal blistering diseases using biopsy and immunofluorescence patterns, and (3) select the correct first-line treatment (topical corticosteroids over systemic).